Liu Pei-Feng, Leung Chung-Man, Chang Yu-Hsiang, Cheng Jin-Shiung, Chen Jih-Jung, Weng Chung-Jeu, Tsai Kuo-Wang, Hsu Chien-Jen, Liu Yen-Chen, Hsu Ping-Chi, Pan Hung-Wei, Shu Chih-Wen
Department of Medical Education and Research; Kaohsiung Veterans General Hospital; Kaohsiung, Taiwan; Department of Biotechnology; Fooyin University; Kaohsiung, Taiwan.
Department of Radiation Oncology; Kaohsiung Veterans General Hospital; Kaohsiung, Taiwan; Department of Safety, Health and Environmental Engineering; National Kaohsiung First University of Science and Technology; Kaohsiung, Taiwan.
Autophagy. 2014 Aug;10(8):1454-65. doi: 10.4161/auto.29556. Epub 2014 Jun 12.
Autophagy is reported to suppress tumor proliferation, whereas deficiency of autophagy is associated with tumorigenesis. ATG4B is a deubiquitin-like protease that plays dual roles in the core machinery of autophagy; however, little is known about the role of ATG4B on autophagy and proliferation in tumor cells. In this study, we found that ATG4B knockdown induced autophagic flux and reduced CCND1 expression to inhibit G 1/S phase transition of cell cycle in colorectal cancer cell lines, indicating functional dominance of ATG4B on autophagy inhibition and tumor proliferation in cancer cells. Interestingly, based on the genetic and pharmacological ablation of autophagy, the growth arrest induced by silencing ATG4B was independent of autophagic flux. Moreover, dephosphorylation of MTOR was involved in reduced CCND1 expression and G 1/S phase transition in both cells and xenograft tumors with depletion of ATG4B. Furthermore, ATG4B expression was significantly increased in tumor cells of colorectal cancer patients compared with adjacent normal cells. The elevated expression of ATG4B was highly correlated with CCND1 expression, consistently supporting the notion that ATG4B might contribute to MTOR-CCND1 signaling for G 1/S phase transition in colorectal cancer cells. Thus, we report that ATG4B independently plays a role as a positive regulator on tumor proliferation and a negative regulator on autophagy in colorectal cancer cells. These results suggest that ATG4B is a potential biomarker and drug target for cancer therapy.
据报道,自噬可抑制肿瘤增殖,而自噬缺陷与肿瘤发生有关。ATG4B是一种去泛素样蛋白酶,在自噬的核心机制中发挥双重作用;然而,关于ATG4B在肿瘤细胞自噬和增殖中的作用知之甚少。在本研究中,我们发现敲低ATG4B可诱导自噬通量并降低CCND1表达,从而抑制大肠癌细胞系中细胞周期的G1/S期转换,表明ATG4B在癌细胞的自噬抑制和肿瘤增殖中起功能主导作用。有趣的是,基于自噬的基因和药物消融,沉默ATG4B诱导的生长停滞与自噬通量无关。此外,在ATG4B缺失的细胞和异种移植肿瘤中,MTOR的去磷酸化参与了CCND1表达的降低和G1/S期转换。此外,与相邻正常细胞相比,结直肠癌患者肿瘤细胞中ATG4B表达显著增加。ATG4B的高表达与CCND1表达高度相关,一致支持ATG4B可能有助于结直肠癌细胞中MTOR-CCND1信号传导促进G1/S期转换的观点。因此,我们报道ATG4B在结直肠癌细胞中独立地作为肿瘤增殖的正调节因子和自噬的负调节因子发挥作用。这些结果表明,ATG4B是癌症治疗的潜在生物标志物和药物靶点。